Merit Medical (MMSI) Q1 2025: Tariff Headwinds Trigger $26M Cost Surge, Offsetting Double-Digit Revenue Growth

2025-04-25 | By EarningsIQ Research

Merit Medical’s first quarter delivered double-digit constant currency revenue growth and margin expansion, but a $26.3 million tariff-driven cost headwind forced a sharp reset to full-year profit guidance. Management’s disciplined execution and ongoing cost initiatives underpin confidence in core growth, though tariff volatility and China exposure now dominate the risk calculus for 2025.

Summary

• Tariff Shock Resets EPS Trajectory: New and retaliatory tariffs drive a $26.3 million cost increase, sharply reducing full-year profit expectations.
• Operational Momentum Persists: Underlying U.S. and OEM demand remains robust, with gross margin gains preceding tariff impact.
• Mitigation Levers in Focus: Management leans on cost initiatives and supply chain agility to offset up to 45% of tariff impact by 2026.

Performance Analysis

Merit Medical posted constant currency revenue growth of 10.9% in Q1, with total revenue reaching $355.4 million. The cardiovascular segment grew 9% (6.2% organic), while endoscopy surged 64% (flat organically), both benefiting from recent acquisitions—Cook Medical’s lead management and Endogastric Solutions. U.S. sales outpaced international, up 14% constant currency, while APAC, especially China, underperformed with a 10% sales decline, attributed to broader macro softness rather than volume-based procurement, VBP, which remained in line with expectations.

Gross margin expanded by 251 basis points to 53.4%, driven by favorable mix, pricing, and operational efficiencies. Operating margin hit a Q1 record at 19.3%, up 229 basis points year-over-year. However, free cash flow fell 20% to $19.5 million, reflecting planned capex for a new distribution center and higher working capital. The company’s net leverage remains conservative at 1.8x. Despite strong core trends, a $26.3 million tariff impact—mostly tied to U.S.-China trade—forced a reset of non-GAAP EPS guidance, now $3.29–$3.42 (down from $3.58–$3.70).

• OEM Outperformance: U.S. OEM sales jumped 21%, far ahead of guidance, though international OEM was softer due to macro headwinds.
• Acquisitions Drive Segment Growth: Recent M&A contributed $15.8 million to Q1 revenue, with integration proceeding as planned.
• China Remains Volatile: 94% of the tariff impact is China-related, and Q1 sales missed expectations, but full-year China guidance remains unchanged.

Underlying business momentum is strong, but the tariff-driven cost surge will pressure margins for the remainder of 2025. Management’s focus is now on operational levers and cost mitigation to preserve profitability.

Executive Commentary

Strategic Positioning

1. Tariff Disruption and Cost Mitigation

Tariff escalation has become the dominant external risk, with $26.3 million in incremental 2025 costs, mostly from retaliatory Chinese tariffs on U.S. exports. Management expects to offset up to 45% of this impact through CGI, continued growth initiatives, such as product line efficiency, supply chain rerouting, and leveraging the company’s Mexican manufacturing footprint. However, most mitigation benefits are delayed until 2026, leaving 2025 margins exposed.

2. U.S. Growth and Product Mix

U.S. sales strength continues to anchor growth, with double-digit gains in core cardiovascular and OEM products. Management attributes this to new account wins, quality and reliability, and the integration of recent M&A. The company’s ability to drive higher-margin product mix and pricing improvements has been a key lever for margin expansion, even as tariffs threaten to unwind some of those gains.

3. China and International Volatility

China’s revenue shortfall in Q1 was attributed to macro softness, not VBP or trade disruption, and guidance for the full year remains unchanged. However, the region’s exposure to tariff-related costs and ongoing geopolitical uncertainty make it a critical watchpoint for both top-line and profit trajectory. Management is not making long-term strategic shifts in response, instead relying on local teams and daily operational reviews to adapt as needed.

4. M&A Integration and Pipeline

Recent acquisitions are delivering as planned, contributing to segment growth and expanding Merit’s product offerings. Integration is on track, with sales force alignment and inventory management supporting a stronger second half in endoscopy. Management notes a busy M&A pipeline, as portfolio reshuffling in the sector creates opportunities for targeted deals.

5. Rhapsody CIE and Reimbursement Tailwinds

Rhapsody CIE, a novel device for vascular access intervention, continues to progress, with positive trial data and a favorable NTAP (new technology add-on payment) recommendation from CMS. This could unlock additional reimbursement in 2026, supporting future U.S. growth. The product’s cadence is expected to skew toward the second half of 2025 as reimbursement clarity improves.

Key Considerations

Merit Medical’s Q1 underscores the company’s operational discipline and strategic resilience, but also exposes the degree of external risk from tariffs and China. Investors must weigh robust core growth and margin gains against the magnitude and timing of cost headwinds.

Key Considerations:

• Tariff Headwinds Dominate 2025 Margin Outlook: $26.3 million in incremental costs will drive a 140–180 basis point drop in non-GAAP operating margin, with most mitigation delayed until 2026.
• OEM and U.S. Demand Remain Robust: High single- to double-digit growth in U.S. OEM and cardiovascular segments offsets international softness.
• Acquisition Integration on Track: Cook Medical and Endogastric Solutions are contributing to top-line growth, with second-half weighting expected for endoscopy.
• Free Cash Flow Guidance Maintained: Despite profit headwinds, management reaffirmed $150 million in free cash flow for 2025, aided by working capital management and capex discipline.
• China Exposure Remains a Swing Factor: 94% of tariff impact is China-linked, and while guidance is unchanged, any further trade escalation or macro deterioration could force additional revisions.

Risks

Tariff and trade policy volatility present the most acute near-term risk, with potential for further cost escalation or retaliatory actions beyond those currently modeled. China macro conditions and policy remain unpredictable, and while management is not making long-term strategic shifts, reliance on local execution introduces operational risk. M&A integration, while progressing, could face disruption if external conditions deteriorate. Investors should also monitor reimbursement timing for Rhapsody CIE and any shifts in U.S. hospital purchasing behavior as cost pressures rise.

Forward Outlook

For Q2 2025, Merit Medical guided to:

• GAAP revenue growth of 8.6%–11.1%, with constant currency organic revenue up 4%–6%.
• Non-GAAP operating margin of 17%–18.75% (down from 20.1% last year).
• Non-GAAP EPS of $0.80–$0.90 (vs. $0.92 last year).

For full-year 2025, management maintained revenue guidance (8%–10% GAAP), but reduced non-GAAP EPS to $3.29–$3.42, reflecting the full tariff impact. Free cash flow guidance remains at $150 million.

• Tariff mitigation efforts will not materially benefit 2025, but management targets offsetting up to 45% of annualized impact by 2026.
• Rhapsody CIE U.S. revenue expected at $7–$9 million, with reimbursement decisions anticipated by June 2025.

Takeaways

Merit Medical’s core business fundamentals remain intact, but tariff-driven cost inflation will weigh on near-term profit and margin expansion. Management’s focus on cost initiatives, supply chain agility, and disciplined capital allocation will be critical for navigating volatility and preserving long-term growth.

• Margin Pressure Is Structural in 2025: Investors should expect lower operating leverage until tariff mitigation strategies take hold in 2026.
• China and Trade Remain Key Watchpoints: Any escalation could force further guidance revisions, while stabilization may unlock upside if mitigation is effective.
• Product Mix and M&A Integration Are Offsetting Factors: Continued focus on higher-margin products and successful integration of acquired assets will be essential to offsetting external headwinds.

Conclusion

Merit Medical’s Q1 2025 results highlight resilient operational execution and robust core demand, but the company now faces a materially higher cost structure due to tariffs. The next several quarters will test management’s ability to execute cost mitigation and maintain growth amid persistent external volatility.

Industry Read-Through

Merit Medical’s tariff-driven profit reset is a cautionary signal for all U.S. medical device exporters with China exposure. The ability to pass through costs, reroute supply chains, and accelerate operational efficiency will define winners in the sector. M&A activity is likely to increase as companies reassess portfolios and seek scale to absorb external shocks. Reimbursement clarity for novel devices like Rhapsody CIE will remain a key growth lever, while OEM demand strength suggests continued resilience in U.S. healthcare capital spending. Persistent geopolitical risk and cost volatility will force more frequent guidance revisions and reward those with flexible, multi-region operations.

MMSI Health Care Medical Devices Tariffs China OEM Acquisition Margin